Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: Clinical evaluation and biological hypothesis

International Journal of Biological Markers

Volumn 12, Issue 1, 1997, Pages 22-26

  Giovanella, L ^a   Piantanida, R ^a   Ceriani, L ^a   Bandera, M ^a   Novario, R ^a   Bianchi, L ^a   Roncari, G ^a  

^a OSPEDALE DI CIRCOLO   (Italy)

Author keywords

CYFRA 21.1; Lung cancer; NSE; SCLC; Tumor markers

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; FOLLOW UP; HUMAN; LUNG DISEASE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; PATIENT MONITORING; PROGNOSIS; TREATMENT OUTCOME;

EID: 0030917483     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089701200105     Document Type: Article

References (21)

1. Stjernsward J, Stanley K. Etiology, epidemiology and prevention of lung cancer. Lung Cancer 1988; 4: 11-24.
2. Klastersky J. Commentary: intensive chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1989; 25: 933-7.
3. Hansen HH, Kristjansen PEG. Chemotherapy of small cell lung cancer. Eur J Cancer 1991; 27: 324-49.
4. Jarvisalo J, Hakama M, Kneckt P, et al. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening. Cancer 1993; 71: 1982-8.
5. Rapellino M, Niklinski J, Pecchio F, et al. Cyfra 21.1 as tumor marker for bronchogenic carcinoma. Eur Respir J 1996; 8: 407.
6. Rastel D, Ramaioli A, Coenillie F, Thirion B. Cyfra 21.1 a sensitive and specific new tumor marker for squamous cell lung cancer: report of the first European Multicentre Evaluation; Eur J Cancer 1994; 30: 601-6.
7. Broers JLV, Rot MK, Oostendorp T, et al. Immunohistochemical detection of human lung heterogeneity using antibodies to ephitelial, neuronal and neuroendocrine antigens. Cancer Res 1987; 47: 3225-34.
8. The Working Group on Tumor Marker Criteria. Tumor Biol 1990; 11: 287-8.
9. Stieber P, Hasholzner U, Bodenmuller H, et al. Cyfra 21.1: a new marker in lung cancer. Cancer 1993; 72: 707-13.
10. Seregni E, Botti C, Bogni A, Bombardieri E. Tumor marker evaluation in patients with lung cancer. Scand J Clin Lab Invest 1995; 55 (Suppl): 67-71.
11. Seregni E, Foa P, Bogni A, et al. Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC): comparison with TPA, CEA, SCC and NSE. Oncology Reports 1996; 3: 95-101.
12. Muller LC, Gasser R, Huber H, et al. Neuron specific enolase (NSE) in small cell lung cancer: longitudinal tumor marker evaluation: Lung Cancer 1992; 8: 29-36.
13. Jorgens LG, Osterlind K, Hansen HH, Cooper EH. The prognostic influence of serum neuron specific enolase in small cell lung cancer. Br J Cancer 1988; 58: 805-7.
14. Akoung GM, Scarna HM, Milleron BJ, Benichou MP, Herman DP. Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. Chest 1985; 87: 39-43.
15. Harding M, McAllister J, Hulks G, Veron D, Monie R, Paul J, Kaye SB. Neuron specific enolase (NSE) in small cell lung cancer: a tumor marker of prognostic significance? Br J Cancer 1990; 61: 605-7.
16. Moll R, Franke WW, Schiller DL, Geiber B, Kreper R. The catalogo of human cytokeratins: patterns of expression in normal epithelia, tumor and cultured cells. Cell 1982; 31: 11-24.
17. Hoefler H, Denk H. immunohistochemical demonstration of cytokeratins in gastrointestinal carcinoids and their probable precursor cells. Virchows Arch B Cell Pathol 1984; 403: 235-40.
18. Pujol JL, Simony J, Laurent JC, et al. Phenotypic heterogenity studied by immunohistochemistry and aneuploidy in non small cell lung cancers. Cancer Res 1989; 49: 2797-802.
19. Broers JLV, Camey DN, De Ley L, Vooijs GP, Ramaerk FCS. Differential expression of intermediate filament proteins distinguishes classic from variant cell lung cancer cell lines. Proc Natl Acad Sci USA 1985; 82: 4409-13.
20. Stieber P, Dienemann H, Hashdtaner U, et al. Comparison of cytokeratin fragment 19 (cyfra 21.1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumor markers in lung cancer. Eur J Clin Chem Clin Biochem 1993; 31: 689-94.
21. Pujol JL, Grenier J, Daures JP, Dever A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by Cyfra 21.1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993; 53: 61-6.